What is the Role of the Anti-Parasitic Drugs in the Treatment of Coronavirus Disease 2019?
Novelty in Biomedicine,
Vol. 9 No. 1 (2021),
8 February 2021
,
Page 31-32
https://doi.org/10.22037/nbm.vi.31803
Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). The first report of the novel coronavirus, SARS-CoV-2, originated in Wuhan, China, in early December 2019 . Currently, there are no U.S. Food and Drug Administration (FDA)–approved drugs for the treatment of patients with COVID-19. A great deal of effort is ongoing to find effective therapeutics and preventive measures against this transmissible virus with high mortality. As result, available data are limited, and there are minimal randomized controlled trial (RCT) data on the efficacy of antiviral or immunomodulatory agents for the treatment of COVID-19 . Most of the treatment protocols are based on observational studies and anecdotic reports.
- COVID-19, Treatment, Anti-parasitic drugs, Hydroxychloroquine, Chloroquine
How to Cite
References
2. Keshtkar-Jahromi M, Bavari S. A call for randomized controlled trials to test the efficacy of chloroquine and hydroxychloroquine as therapeutics against novel coronavirus disease (COVID-19). The American Journal of Tropical Medicine and Hygiene. 2020;102(5):932.
3. Calvo C, Tagarro A, Otheo E, Epalza C, de la Infección GdS, editors. Actualización de la situación epidemiológica de la infección por SARS-CoV-2 en España. Comentarios a las recomendaciones de manejo de la infección en pediatría. Anales De Pediatria (Barcelona, Spain: 2003); 2020: Elsevier.
4. Vollaard A, Gieling E, van der Linden P, Sihna B, de Boer M. Medicamenteuze behandelopties bij patiënten met COVID-19 (infecties met SARS-CoV-2). 2020.
5. Siddiqui AJ, Jahan S, Ashraf SA, Alreshidi M, Ashraf MS, Patel M, et al. Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2. Journal of Biomolecular Structure and Dynamics. 2020:1-14.
6. Collins KL. Profitable gifts: a history of the Merck Mectizan donation program and its implications for international health. Perspectives in biology and medicine. 2004;47(1):100-9.
7. Kipp W, Bamhuhiiga J, Rubaale T, BÜTTNER DW. ADVERSE REACTIONS TO IVERMECTIN TREATMENT IN SIMULIUM NEAVEI–TRANSMITTED ONCHOCERCIASIS. The American journal of tropical medicine and hygiene. 2003;69(6):621-3.
8. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral research. 2020:104787.
9. Cong Y, Gross R, Zhou H, Frieman M, Bollinger L, Wada J, et al. MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells. PloS one. 2018;13(3):e0194868.
10. Beura S, Prabhakar C. In-silico strategies for probing chloroquine based inhibitors against SARS-CoV-2. Journal of Biomolecular Structure and Dynamics. 2020(just-accepted):1-25.
11. Sinha N, Balayla G. Hydroxychloroquine and covid-19. Postgraduate Medical Journal. 2020.
12. Choudhary R, Sharma AK. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New Microbes and New Infections. 2020:100684.
13. Nord JE, Shah PK, Rinaldi RZ, Weisman MH, editors. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Seminars in arthritis and rheumatism; 2004: Elsevier.
- Abstract Viewed: 345 times
- PDF Downloaded: 233 times